Previous 10 | Next 10 |
home / stock / casbf / casbf news
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CanSino Biologics (OTCMKTS: CASBF ) are ripping higher on Wednesday, with CASBF stock up about 75% on the day. The move is startling, particularly given the poor price action we were seeing in the overall stock market...
Vaccine maker CanSino Biologics Inc. ( OTCPK:CASBF ) added ~76% on Wednesday after the company announced that more Chinese cities follow Shanghai in deploying its inhaled COVID-19 vaccine. The Tianjin-based company said in its official social media account that 13 Chinese ...
Summary Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment. Nanjing Frontier Biotechnologies completed a $29 million private placemen...
Chinese regulators have approved an inhaled version of a COVID-19 vaccine developed by Tianjin-based CanSino Biologics Inc. ( OTCPK:CASBF ) as a booster dose, the company announced over the weekend. The vaccine branded as Convidecia Air allows the formation of an aerosol f...
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in a $125 million agreement. Oncotelic Therapeutics, a South San Francisco company, formed a Hong Kong JV with Dragon Overseas Capital to develop TGF-β therapeutics. ...
CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO. The approval could have limited benefits for the company as the pandemic fades and other products are widely available. Judging from valuation alone, invest...
The World Health Organization (WHO) on Thursday issued an emergency use listing for a single-dose COVID-19 shot developed by China-based vaccine maker CanSino Biologics (OTCPK:CASBF). Convidecia vaccine, based on a modified human adenovirus expressing the spike S protein of the COVID-19 virus...
China’s leading biotechnology and other health care companies have continued to grow revenues rapidly over the past two years and are expected to see strong growth in the years to come. Recently, concerns over domestic regulation, increased domestic competition, US Food and Dru...
A group of global institutions led by the International Monetary Fund (IMF) has proposed $15 billion in grants this year and $10 billion annually thereafter as part of a global strategy to address the long-term risks of COVID-19. The IMF, in partnership with the Coalition for Epidemic Prepare...
Chinese regulators have cleared clinical studies for two Covid-19 vaccines developed by local pharmaceutical companies, CanSino Biologics (OTCPK:CASBF) and CSPC Pharmaceutical (OTC:CHJTF), (OTCPK:CHPTY) (OTCPK:CSPCY). The National Medical Products Administration of China (NMPA) has given the ...